跳至主要内容
临床试验/NCT06800417
NCT06800417尚未招募不适用

Performance and Safety of the Innofix® Screw as Part of Stabilization of a Non-displaced Pathologic Fracture (Complete or Impending) of the Pelvic Bone of Cancer Patients by Mini-invasive Percutaneous Fixation by Internal Cemented Screw

Innoprod Medical0 个研究点目标入组 34 人开始时间: 2025年5月1日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
34
主要终点
Rate of patients which have a pain reduction rate, at 6 weeks postoperatively, equal or superior to 30%

研究概览

简要总结

The purpose of this clinical investigation is to collect data about the safety and the performances of the InnoFix® screw : Clinical performances (Pain reduction due to the fracture treatment, maintenance of the stabilizaton of the treated fracture and mobility improvement) / Technical performances (Percutaneous implantation by mini-invasive approach, Efficiency of percutaneous implementation and efficiency of percuatneous cementing) / Safety performances (Preservation of the screw stability after implantation and preservation of the screw integrity after implantation). The safety and performance data about the InnoFix® screw will be used to obtain their CE marking according to the regulation (EU) 2017/745.

The principal objective of this clinical investigation is to assess the postoperative reduction in pain level of the patient at 6 weeks follow-up.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patient is 18 years old or more
  • The patient is a cancer patient
  • The patient needs a stabilization of a non-displaced pathologic fracture (complete or impending) of the pelvic bone
  • The patient is symptomatic with musculoskeletal pain exacerbated during movement or weight bearing
  • The patient has been informed and he has signed the informed consent
  • The patient must be willing and able to comply with all study requirements including follow-up visits and radiographic assessments
  • The patient is affiliated with the French social security system

排除标准

  • The patient has got a displaced fracture or an unstable fracture justifying conventional surgical fixation
  • The patient is a pregnant woman or considered getting pregnant during its investigation participation
  • The patient presents medical conditions that could have an impact on the clinical investigation (under responsibility of the investigator)
  • The patient has got one or more contraindications to general anaesthesia
  • The patient has got an insufficient bone strength (severe osteoporosis, local infection, or tumor osteolysis) precluding a correct and long-term fixation
  • The use of the InnoFix® screw can interfere with anatomical structures or physiological performances
  • The patient has got an insufficient tissue coverage at the surgical site
  • The patient has got a sepsis, fever, subcutaneous or cutaneous infection on the implantation way, deep abscess in contact with the fracture site
  • The patient has got a mental or neuromuscular disorder that may cause fixation failure or postoperative complications
  • The patient is allergic and/or hypersensitive to a component of the InnoFix® modules, of the InnoTool™ instruments and to the used cement
  • The patient has got a haemostasis disorder ((INR >1.5, platelets <50x109/L)
  • The patient participates to another clinical investigation
  • The patient's life expectancy is lower than 6 months
  • The patient is under guardianship, curatorship or legal protection
  • The patient is deprived of liberty by a judicial or administrative decision

结局指标

主要结局

Rate of patients which have a pain reduction rate, at 6 weeks postoperatively, equal or superior to 30%

时间窗: From the patient inclusion date to 6 weeks postoperatively

Pain reduction is measured with the VAS scale : Zero is equivalent to no pain and 10 indicates the worst possible pain

次要结局

  • Implantation success rate of the InnoFix® screw(At the end of surgery)
  • Rate of InnoFix® screws with their integrity preserved postoperatively(From end surgery to 6 weeks and 6 months postoperatively)
  • Satisfaction rate of the radiologist regarding the efficiency of the percutaneous implementation(At the end of surgery)
  • Satisfaction rate of the radiologist regarding the efficiency of the percutaneous cementing(At the end of surgery)
  • Rate of stable InnoFix® screws postoperatively(From end surgery to 6 weeks and 6 months postoperatively)
  • Rate of patients which have a pain reduction rate, at 6 months postoperatively, equal or superior to 30%(From the patient inclusion date to 6 months postoperatively)
  • Rate of patient which have had, at least, one adverse event in relation with the InnoFix® screw postoperatively(From the patient inclusion date to 6 months postoperatively)
  • Rate of patient which have had, at least, one serious adverse event in relation with the InnoFix® screw postoperatively(From the patient inclusion date to 6 months postoperatively)
  • Rate of postoperative stable fractures(From end surgery to 6 weeks and 6 months postoperatively)
  • Rate of patients which have a mobility improvement rate postoperatively(From the patient inclusion date to 6 weeks and 6 months postoperatively)

研究者

发起方
Innoprod Medical
申办方类型
Industry
责任方
Sponsor

相似试验